IVA vs MLTX: stock comparison and AI forecast
Inventiva S.A. (IVA) and Moonlake Immunotherapeutics (MLTX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
IVA Inventiva S.A.
- Price
- $4.03 -25.6% · 6M
- Market Cap
- $940M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
MLTX Moonlake Immunotherapeutics
- Market Cap
- $984M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- IVA and MLTX have similar market capitalizations ($940M and $984M).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | IVA | MLTX |
|---|---|---|
| Market Cap | $940M | $984M |
| EPS | – | $-3.33 |
| Revenue/Share | $0.09 | – |
| FCF/Share | – | $-2.87 |
Profitability & Margins
| Metric | IVA | MLTX |
|---|---|---|
| Operating Margin | -1040.1% | – |
| Net Margin | -1034.0% | – |
| Tax Rate | – | -0.6% |
Financial Health
| Metric | IVA | MLTX |
|---|---|---|
| Current Ratio | – | 9.13x |
| Interest Coverage | – | -37.0x |
| Working Capital | – | $475M |
Cash Flow
| Metric | IVA | MLTX |
|---|---|---|
| Operating Cash Flow | -$182M | -$244M |
| Free Cash Flow | – | -$244M |
| Capital Spending | – | $0.00M |
Income Statement
| Metric | IVA | MLTX |
|---|---|---|
| Total Revenue | $20M | – |
| Operating Income | -$210M | -$277M |
| Net Income | -$209M | – |
| R&D Expense | $202M | $230M |
Dividend & Shareholder Information
| Metric | IVA | MLTX |
|---|---|---|
| Shares Outstanding | 243M | 85M |
IVA vs MLTX: stock comparison and AI forecast
Which is bigger, IVA or MLTX?
IVA and MLTX have similar market capitalizations ($940M and $984M).
Which one does Intratio's AI model rank higher, IVA or MLTX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.